Acumen Pharmaceuticals, Inc.
ABOS
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -113.28M | -121.34M | -133.35M | -136.67M | -116.25M |
| Total Depreciation and Amortization | 185.00K | 184.00K | 183.00K | 181.00K | 179.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.04M | 10.73M | 9.40M | 7.85M | 5.24M |
| Change in Net Operating Assets | -3.50M | -5.12M | 108.00K | 10.87M | 8.36M |
| Cash from Operations | -105.55M | -115.54M | -123.66M | -117.76M | -102.48M |
| Capital Expenditure | -9.00K | -88.00K | -88.00K | -88.00K | -84.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 91.45M | 134.02M | 137.43M | 86.79M | 86.00M |
| Cash from Investing | 91.44M | 133.93M | 137.35M | 86.70M | 85.92M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Common Stock | 147.00K | 39.00K | 37.00K | 37.00K | 37.00K |
| Repurchase of Common Stock | -149.00K | -73.00K | -82.00K | -82.00K | -82.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 35.75M | -- | 0.00 | -42.00K | -170.00K |
| Cash from Financing | 35.74M | -34.00K | -45.00K | -87.00K | -215.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.64M | 18.36M | 13.64M | -31.15M | -16.77M |